application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

Please amend the application as follows:

In the Specification:

In the specification at page 51, please delete the paragraph appearing at lines 21-29 and substitute therefor the following paragraph:

-- Plasmid pEZ13835 (Figure 6; *attP*), pEZC7501 (Figure 7; *attB*), pEZ11104 (Figure 8; *attR*), and pEZC8402 (Figure 9; *attL*) were as shown. pEZC7501 was cut with *Sca*I and pEZC8402 with *Nco*I before use. pEZ13835 and pEZC8402 were propagated in *E. coli* DB2 and the other two in *E. coli* DH5α. Cells from a glycerol seed were placed in 25 ml of CIRCLEGROW® brand culture medium (BIO 101) plus 100 mg/ml ampicillin (pEZC7501 and pEZC8402) or plus 100 mg/ml kanamycin (pEZ13835 and pEZ11104) and grown overnight at 37 °C. Cells were harvested by centrifugation and stored at - 70 °C. Plasmid DNAs were purified using Qiagen Midi products and protocols. --

---

In the specification at pages 62-63, please delete the paragraph appearing at page 62, line 27, through page 63, line 4, and substitute therefor the following paragraph:

-- *Growth of Cells.* Cells from a glycerol stock of BL21DE3 bearing plasmid pET12AS20AA were inoculated into 3 ml of LB broth containing 100 mg/ml ampicillin. This inoculum was diluted into LB broth + 100 mg/ml ampicillin 1:100 and the 300-ml culture was grown overnight at 30 °C. The A_{650} of the culture should not exceed 1.0. This culture was used to innoculate 10 flasks containing 500 ml each of CIRCLEGROW® brand culture medium (BIO 101) plus 100 mg/ml ampicillin plus 1 mM $MgSO_4$. Cells were grown at 37 °C until the A_{650} was 0.5 and expression of S20 was induced by the addition of IPTG to 0.5 mM. After growth at 37 °C for 4 hours, cells were harvested by centrifugation at 4 °C and stored at -70 °C. --

In the Claims:

Please cancel claims 1-13 and 52-64, without prejudice to or disclaimer of the subject matter encompassed thereby. Applicants reserve the right to pursue the subject matter of claims these claims in the present application and/or in one or more continuing and/or divisional applications.

Please substitute the following claim 14 for currently pending claim 14:

14. (Once amended) A method for cloning or subcloning one or more desired nucleic acid molecules comprising

(a) forming a combination by combining *in vitro*